Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	15.08	15.4	24.91	29.52	17.59
Research & Development	18.59	9.25	25.18	60.8	61.31
Operating Expenses	33.67	24.64	50.09	90.32	78.89
Operating Income	-33.67	-24.64	-50.09	-90.32	-78.89
Interest & Investment Income	2.93	3.48	1.07	0.62	2.04
Currency Exchange Gain (Loss)	-0.68	0	-0.77	-0.25	-
EBT Excluding Unusual Items	-31.42	-21.16	-49.79	-89.95	-76.85
Merger & Restructuring Charges	-2.5	-2.5	-1.1	-	-
Impairment of Goodwill	-17.13	-	-0.83	-	-
Gain (Loss) on Sale of Assets	-	-0.04	-0.09	-	-
Asset Writedown	-	-5.97	-0.14	-	-
Other Unusual Items	-5.69	-1.92	-	-	-
Pretax Income	-56.74	-31.58	-51.94	-89.95	-76.85
Income Tax Expense	0.09	-0.2	-0.28	-	-
Net Income	-56.83	-31.39	-51.66	-89.95	-76.85
Net Income to Common	-56.83	-31.39	-51.66	-89.95	-76.85
Shares Outstanding (Basic)	43	37	33	30	29
Shares Outstanding (Diluted)	43	37	33	30	29
Shares Change (YoY)	16.18%	11.17%	12.71%	1.86%	53.30%
EPS (Basic)	-1.31	-0.84	-1.54	-3.03	-2.63
EPS (Diluted)	-1.31	-0.84	-1.54	-3.03	-2.63
Free Cash Flow	-32.16	-18.45	-44.17	-63.11	-50.87
Free Cash Flow Per Share	-0.74	-0.50	-1.32	-2.12	-1.74
EBITDA	-33.48	-24.32	-49.89	-89.97	-78.56
D&A For EBITDA	0.19	0.32	0.2	0.34	0.33
EBIT	-33.67	-24.64	-50.09	-90.32	-78.89

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q